decisionhealth Newsletters, Part B News - 2006 Issue 9 (September)
OIG slams $130 chemotherapy demo payments
Subscribe or sign in to view the full article.
Article Overview
This article summarizes an OIG critique of a CMS oncology demonstration project tied to chemotherapy-related patient reporting and a later follow-on demonstration for cancer E/M services. It discusses program scope, data quality concerns, overall spending, overpayment findings, and why the issue matters to oncology practices, Medicare policy watchers, and coding/reimbursement professionals.
Why This Topic Matters
The article highlights how demonstration program structure, reporting requirements, and billing patterns can affect Medicare payment integrity and audit risk for oncology services.
What You Will Learn
- How CMS oncology demonstration projects were structured and evaluated
- What the OIG reported about data quality and program oversight
- Why demonstration payment activity drew concern from Medicare oversight bodies
- What types of financial and billing issues were identified in the review
Who Should Read This
- Oncology coders
- Medical billing professionals
- Compliance officers
- Practice administrators
- Medicare policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com